Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Wittwer NL, Brumatti G, Marchant C, Sandow JJ, Pudney MK, Dottore M, D'Andrea RJ, Lopez AF, Ekert PG, Ramshaw HS.

Blood Adv. 2017 Jun 20;1(15):1067-1079. doi: 10.1182/bloodadvances.2016002931. eCollection 2017 Jun 27.

2.

MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death.

Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurien L, Kim C, Jamal K, Wicky John S, Liccardi G, Chau D, Murphy JM, Brumatti G, Feltham R, Pasparakis M, Silke J, Meier P.

Mol Cell. 2017 Jun 1;66(5):698-710.e5. doi: 10.1016/j.molcel.2017.05.003. Epub 2017 May 11.

3.

Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.

Sandow JJ, Infusini G, Holik AZ, Brumatti G, Averink TV, Ekert PG, Webb AI.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201700013. Epub 2017 May 15.

PMID:
28447382
4.

DR5 and caspase-8 are dispensable in ER stress-induced apoptosis.

Glab JA, Doerflinger M, Nedeva C, Jose I, Mbogo GW, Paton JC, Paton AW, Kueh AJ, Herold MJ, Huang DC, Segal D, Brumatti G, Puthalakath H.

Cell Death Differ. 2017 May;24(5):944-950. doi: 10.1038/cdd.2017.53. Epub 2017 Apr 14.

5.

'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia.

Brumatti G, Lalaoui N, Wei AH, Silke J.

Trends Mol Med. 2017 Mar;23(3):264-281. doi: 10.1016/j.molmed.2017.01.005. Epub 2017 Feb 11. Review.

PMID:
28196625
6.

Relevance of necroptosis in cancer.

Lalaoui N, Brumatti G.

Immunol Cell Biol. 2017 Feb;95(2):137-145. doi: 10.1038/icb.2016.120. Epub 2016 Dec 6. Review.

PMID:
27922620
7.

Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia.

Narayan N, Morenos L, Phipson B, Willis SN, Brumatti G, Eggers S, Lalaoui N, Brown LM, Kosasih HJ, Bartolo RC, Zhou L, Catchpoole D, Saffery R, Oshlack A, Goodall GJ, Ekert PG.

Leukemia. 2017 Apr;31(4):808-820. doi: 10.1038/leu.2016.279. Epub 2016 Oct 14.

PMID:
27740637
8.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

9.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.

Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. Erratum in: Sci Transl Med. 2017 May 31;9(392):.

PMID:
27194727
10.

Lentiviral Vectors to Analyze Cell Death Regulators.

Nachbur U, Brumatti G.

Methods Mol Biol. 2016;1419:265-76. doi: 10.1007/978-1-4939-3581-9_19.

PMID:
27108445
11.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

12.

Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.

Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, Ekert PG, Ramshaw HS, D'Andrea RJ.

J Leukoc Biol. 2014 Jul;96(1):83-91. doi: 10.1189/jlb.2AB1013-559R. Epub 2014 Mar 5.

PMID:
24598054
13.

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Brumatti G, Salmanidis M, Kok CH, Bilardi RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP, Okamoto T, Bouillet P, D'Andrea RJ, Ekert PG.

Oncotarget. 2013 Nov;4(11):1933-47.

14.

Seeking a MCL-1 inhibitor.

Brumatti G, Ekert PG.

Cell Death Differ. 2013 Nov;20(11):1440-1. doi: 10.1038/cdd.2013.114. No abstract available.

15.

Hoxb8 regulates expression of microRNAs to control cell death and differentiation.

Salmanidis M, Brumatti G, Narayan N, Green BD, van den Bergen JA, Sandow JJ, Bert AG, Silke N, Sladic R, Puthalakath H, Rohrbeck L, Okamoto T, Bouillet P, Herold MJ, Goodall GJ, Jabbour AM, Ekert PG.

Cell Death Differ. 2013 Oct;20(10):1370-80. doi: 10.1038/cdd.2013.92. Epub 2013 Jul 19.

16.

Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations.

Green BD, Jabbour AM, Sandow JJ, Riffkin CD, Masouras D, Daunt CP, Salmanidis M, Brumatti G, Hemmings BA, Guthridge MA, Pearson RB, Ekert PG.

Cell Death Differ. 2013 Oct;20(10):1341-9. doi: 10.1038/cdd.2013.63. Epub 2013 Jun 21.

17.

Exploring the utility of human DNA methylation arrays for profiling mouse genomic DNA.

Wong NC, Ng J, Hall NE, Lunke S, Salmanidis M, Brumatti G, Ekert PG, Craig JM, Saffery R.

Genomics. 2013 Jul;102(1):38-46. doi: 10.1016/j.ygeno.2013.04.014. Epub 2013 Apr 29.

18.

In vitro differentiation of near-unlimited numbers of functional mouse basophils using conditional Hoxb8.

Gurzeler U, Rabachini T, Dahinden CA, Salmanidis M, Brumatti G, Ekert PG, Echeverry N, Bachmann D, Simon HU, Kaufmann T.

Allergy. 2013;68(5):604-13. doi: 10.1111/all.12140.

PMID:
23590216
19.

Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival.

Elgendy M, Sheridan C, Brumatti G, Martin SJ.

Mol Cell. 2011 Apr 8;42(1):23-35. doi: 10.1016/j.molcel.2011.02.009. Epub 2011 Feb 25.

20.

An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.

Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ.

Oncogene. 2010 Dec 9;29(49):6428-41. doi: 10.1038/onc.2010.380. Epub 2010 Aug 30.

PMID:
20802529
21.

Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Brumatti G, Salmanidis M, Ekert PG.

Cell Mol Life Sci. 2010 May;67(10):1619-30. doi: 10.1007/s00018-010-0288-8. Epub 2010 Feb 16. Review.

PMID:
20157838
22.

Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.

Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, Lavelle EC, Martin SJ.

Immunity. 2009 Jul 17;31(1):84-98. doi: 10.1016/j.immuni.2009.05.007. Epub 2009 Jun 25.

23.

Bicaudal is a conserved substrate for Drosophila and mammalian caspases and is essential for cell survival.

Creagh EM, Brumatti G, Sheridan C, Duriez PJ, Taylor RC, Cullen SP, Adrain C, Martin SJ.

PLoS One. 2009;4(3):e5055. doi: 10.1371/journal.pone.0005055. Epub 2009 Mar 30. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/dbafbfb3-0c37-4e20-931a-8f041ff5d721.

24.

Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.

Sheridan C, Brumatti G, Martin SJ.

J Biol Chem. 2008 Aug 8;283(32):22128-35. doi: 10.1074/jbc.M800271200. Epub 2008 May 27.

25.

Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells.

Brumatti G, Sheridan C, Martin SJ.

Methods. 2008 Mar;44(3):235-40. doi: 10.1016/j.ymeth.2007.11.010. Review.

PMID:
18314054
26.

Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide.

Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP.

Exp Cell Res. 2008 Feb 1;314(3):554-63. Epub 2007 Nov 17.

PMID:
18078929
27.

Establishing a blueprint for CED-3-dependent killing through identification of multiple substrates for this protease.

Taylor RC, Brumatti G, Ito S, Hengartner MO, Derry WB, Martin SJ.

J Biol Chem. 2007 May 18;282(20):15011-21. Epub 2007 Mar 19.

28.

Involvement of DNA replication in ultraviolet-induced apoptosis of mammalian cells.

Batista LF, Chiganças V, Brumatti G, Amarante-Mendes GP, Menck CF.

Apoptosis. 2006 Jul;11(7):1139-48.

PMID:
16703265
29.

Apoptosomes: protease activation platforms to die from.

Adrain C, Brumatti G, Martin SJ.

Trends Biochem Sci. 2006 May;31(5):243-7. Epub 2006 Apr 3. Review.

PMID:
16595176
30.

The cytotoxic lymphocyte protease, granzyme B, targets the cytoskeleton and perturbs microtubule polymerization dynamics.

Adrain C, Duriez PJ, Brumatti G, Delivani P, Martin SJ.

J Biol Chem. 2006 Mar 24;281(12):8118-25. Epub 2006 Jan 16.

31.

TRAIL and immunity: more than a license to kill tumor cells.

Corazza N, Brumatti G, Schaer C, Cima I, Wasem C, Brunner T.

Cell Death Differ. 2004 Dec;11 Suppl 2:S122-5. No abstract available.

32.

Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells.

Ramos MG, Rabelo FL, Brumatti G, Bueno-da-Silva AE, Amarante-Mendes GP, Alvarez-Leite JI.

Chemotherapy. 2004 Nov;50(5):221-8. Epub 2004 Nov 3.

PMID:
15528887
33.

TRAIL and thymocyte apoptosis: not so deadly?

Corazza N, Brumatti G, Jakob S, Villunger A, Brunner T.

Cell Death Differ. 2004 Dec;11 Suppl 2:S213-5. No abstract available.

34.

Effect of cell confluence on ultraviolet light apoptotic responses in DNA repair deficient cells.

Carvalho H, da Costa RM, Chiganças V, Weinlich R, Brumatti G, Amarante-Mendes GP, Sarasin A, Menck CF.

Mutat Res. 2003 Nov;544(2-3):159-66.

PMID:
14644317
35.
36.

Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.

Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP.

Cell Death Differ. 2003 May;10(5):592-8.

37.

Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli.

Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP.

FEBS Lett. 2003 Apr 24;541(1-3):57-63.

38.

Apoptosis induced by butyrate is independent of Jak/STAT signaling in a fibrosarcoma cell line.

Rabelo FL, Ramos MG, Brumatti G, Amarante-Mendes GP, Ropert C, Bonjardim CA, Alvarez-Leite JI.

Biochem Biophys Res Commun. 2003 Feb 21;301(4):968-73.

PMID:
12589807
39.

Photorepair of RNA polymerase arrest and apoptosis after ultraviolet irradiation in normal and XPB deficient rodent cells.

Chiganças V, Batista LF, Brumatti G, Amarante-Mendes GP, Yasui A, Menck CF.

Cell Death Differ. 2002 Oct;9(10):1099-107.

40.

Low amounts of the DNA repair XPA protein are sufficient to recover UV-resistance.

Muotri AR, Marchetto MC, Suzuki MF, Okazaki K, Lotfi CF, Brumatti G, Amarante-Mendes GP, Menck CF.

Carcinogenesis. 2002 Jun;23(6):1039-46.

PMID:
12082027

Supplemental Content

Loading ...
Support Center